LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Home・Aandelen Lijst・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Gesloten

SectorGezondheidszorg

204.48 -1.03

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

204.26

Max

209.93

Belangrijke statistieken
By Trading Economics
Inkomsten	-22M -61M
Verkoop	56M 214M
Winstmarge	-28.549
Werknemers	1,017
EBITDA	-56M -53M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+24.87% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1B 13B
Vorige openingsprijs	205.51
Vorige sluitingsprijs	204.48

Nieuwssentiment

By Acuity

50%

184 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

157.66 / 167.29 Steun & Weerstand

Ascendis Pharma A-S ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 dec 2025, 21:08 UTC

Acquisities, Fusies, Overnames

Meta Platforms Buys AI-Device Maker Limitless

5 dec 2025, 19:39 UTC

Belangrijke Marktbewegers

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

5 dec 2025, 19:17 UTC

Acquisities, Fusies, Overnames

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

5 dec 2025, 21:59 UTC

Acquisities, Fusies, Overnames

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

5 dec 2025, 21:50 UTC

Marktinformatie

Winsten

Financial Services Roundup: Market Talk

5 dec 2025, 21:50 UTC

Acquisities, Fusies, Overnames

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

5 dec 2025, 21:36 UTC

Marktinformatie

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

5 dec 2025, 21:35 UTC

Acquisities, Fusies, Overnames

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

5 dec 2025, 21:26 UTC

Acquisities, Fusies, Overnames

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

5 dec 2025, 21:12 UTC

Marktinformatie

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

5 dec 2025, 21:03 UTC

Marktinformatie

Winsten

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

5 dec 2025, 21:01 UTC

Marktinformatie

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

5 dec 2025, 20:43 UTC

Acquisities, Fusies, Overnames

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

5 dec 2025, 20:43 UTC

Acquisities, Fusies, Overnames

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

5 dec 2025, 20:42 UTC

Acquisities, Fusies, Overnames

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

5 dec 2025, 20:01 UTC

Acquisities, Fusies, Overnames

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

5 dec 2025, 19:44 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

5 dec 2025, 19:44 UTC

Marktinformatie

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

5 dec 2025, 19:39 UTC

Marktinformatie

Silver Climbs to a New Record High -- Market Talk

5 dec 2025, 19:31 UTC

Acquisities, Fusies, Overnames

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 dec 2025, 18:30 UTC

Marktinformatie

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

5 dec 2025, 18:28 UTC

Acquisities, Fusies, Overnames

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 dec 2025, 18:24 UTC

Acquisities, Fusies, Overnames

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

5 dec 2025, 18:20 UTC

Marktinformatie

Baker Hughes Reports Higher U.S. Rig Count -- Market Talk

5 dec 2025, 18:11 UTC

Marktinformatie

The Tale of Two Canadian Employment Indicators -- Market Talk

5 dec 2025, 17:48 UTC

Marktinformatie

Canadian Youth Unemployment Rate Cools -- Market Talk

5 dec 2025, 17:44 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

5 dec 2025, 17:44 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Correction to Imax Market Talk

5 dec 2025, 17:35 UTC

Marktinformatie

Canada Jobs Data Doesn't Jive With Trade Uncertainty, Indicators -- Market Talk

5 dec 2025, 17:25 UTC

Marktinformatie

Canadian Jobs Numbers May Support Rates Hikes Next Year -- Market Talk

Peer Vergelijking

Prijswijziging

Ascendis Pharma A-S ADR Prognose

Koersdoel

By TipRanks

24.87% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 260.46 USD 24.87%

Hoogste 325 USD

Laagste 220 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ascendis Pharma A-S ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

14 ratings

Buy

Hold

Sell

Gebaseerd op 14 analisten die aandelenratings hebben gegeven aan Ascendis Pharma A-S ADR - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

157.66 / 167.29Steun & Weerstand

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

184 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.